Anima Biotech announced positive preclinical data of its lung fibrosis candidate. This drug operates through a novel mRNA biology mechanism of action, opening new avenues for treating idiopathic pulmonary fibrosis patients.
[Anima Biotech]
Home Newsletters Extracellular Matrix News Anima Biotech Announces Preclinical Data of Candidate in Idiopathic Pulmonary Fibrosis
